vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.17M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
VTVT Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
vTv Therapeutics Inc.NASDAQ: VTVT
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$16.34M, compared with $499K a year earlier. Trailing-twelve-month change in working capital was -$18.69M. Over 3 fiscal years it compounded at -29.4% a year.
Context
- Change in working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly change in working capital holds near -$16.34M or moves back toward the trailing-twelve-month quarterly average of -$4.67M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 1.89M USD
- Year-over-year change
- +134.8%
- 4-year CAGR
- +171.2%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.89M | +134.8% |
| FY2024 | 2024-12-31 | (5.44M) | -223.8% |
| FY2023 | 2023-12-31 | 4.39M | -18.4% |
| FY2022 | 2022-12-31 | 5.39M | +15285.7% |
| FY2021 | 2021-12-31 | 35K | — |
Change in Working Capital vs competitors
How VTVT compares with its peers on the latest reported figures
- VTVT's LTM Mar 2026 change in working capital of $18.69M is the 2nd largest of the 9 companies compared; the peer median is $2.39M.
- Its year-over-year change of +942.0% is the 2nd highest of 9, against a peer median of +117.2%.
- Change in working capital amounts to 50.7% of revenue for VTVT, versus a peer median of 63.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.67M | +292.6% | +227.4% | 50.9% | |
| LTM Mar 2026 | $18.69M | +942.0% | -29.4% | 50.7% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $13.32M | +2303.6% | +112.6% | — |
| LTM Mar 2026 | $6.94M | +103.5% | — | 2082.3% | |
| LTM Jun 2026 | $5.38M | -1724.8% | — | 25.6% | |
| LTM Mar 2026 | $3.04M | +607.3% | -27.9% | — | |
| LTM Mar 2026 | $1.74M | -42.1% | +26.3% | 75.9% | |
| LTM Mar 2026 | $939.36K | -29.8% | — | — | |
| LTM Mar 2026 | $850K | +131.0% | — | — | |
| Peer median (excluding VTVT) | $2.39M | +117.2% | +69.5% | 63.4% | |
Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.73M) | (19.16M) | (20.25M) | (22.71M) | (31.08M) |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.36M | 0 | 1.58M | 2.76M | 3.78M |
| Change in Working Capital | 35K | 5.39M | 4.39M | (5.44M) | 1.89M |
| Accounts Receivables | 101K | (116K) | 71K | 40K | 0 |
| Inventory | (889K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.83M | (856K) | 2.93M | 0 | 1.53M |
| Other Working Capital | (1.01M) | 6.36M | 1.39M | (5.48M) | 362K |
| Other Non-Cash Items | (4.06M) | (1.56M) | (4.89M) | (10K) | 142K |
| Operating Cash Flow | (19.31M) | (15.25M) | (19.08M) | (25.31M) | (25.26M) |
| Capital Expenditures | 0 | (21K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 4.4M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 4.4M | 0 | 0 |
| Other Investing Activities | 0 | 0 | (4.4M) | 0 | 0 |
| Investing Cash Flow | 0 | (21K) | 4.4M | 0 | 0 |
| Debt Repayment | 172K | (808K) | (33K) | (191K) | (392K) |
| Common Stock Issued | 26.76M | 14.79M | 12.03M | 52.8M | 77.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 47K | 0 | 0 | 0 | 341K |
| Financing Cash Flow | 26.98M | 13.98M | 12M | 52.61M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.67M | (1.29M) | (2.68M) | 27.3M | 52.19M |
| Free Cash Flow | (19.31M) | (15.27M) | (19.08M) | (25.31M) | (25.26M) |
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.